Striatal dopamine D2 receptors in medication-naive patients with major depressive disorder as assessed with [11C]raclopride PET

Psychopharmacology

Volumn 197, Issue 4, 2008, Pages 581-590

  Hirvonen, Jussi ^a,b   Karlsson, Hasse ^a,c   Kajander, Jaana ^a   Markkula, Juha ^a   Rasi Hakala, Helena ^a   Någren, Kjell ^b   Salminen, Jouko K ^d   Hietala, Jarmo ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d SOCIAL INSURANCE INSTITUTION   (Finland)

Author keywords

D2 receptor; Depression; Dopamine; Imaging; Positron emission tomography

Indexed keywords

DOPAMINE 2 RECEPTOR; RACLOPRIDE C 11; CARBON; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; RACLOPRIDE;

ADULT; ARTICLE; BINDING AFFINITY; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG BINDING; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MEDICAL ASSESSMENT; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; STRIATE CORTEX; THALAMUS; BRAIN MAPPING; CORPUS STRIATUM; HEMISPHERIC DOMINANCE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; REFERENCE VALUE; SCINTISCANNING;

ADULT; BRAIN MAPPING; CARBON RADIOISOTOPES; CORPUS STRIATUM; DEPRESSIVE DISORDER, MAJOR; DOMINANCE, CEREBRAL; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; RECEPTORS, DOPAMINE D2; REFERENCE VALUES; THALAMUS;

EID: 41849091159     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-008-1088-9     Document Type: Article

References (50)

1. 11C]L-dopa in healthy volunteers and patients with unipolar major depression. Depression 1:71-81
2. 2 receptors in depressed suicide victims. Neuropsychobiology 44:70-73
3. 99mTc-TRODAT-1 SPECT study. J Affect Disord 89:115-123
4. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561-71
5. 2 receptor binding sites in brain samples from depressed suicides and controls. Brain Res 752:227-233
6. 99mTc]TRODAT-1 SPECT imaging. Am J Psychiatry 160:1836-1841
7. D'Aquila PS, Collu M, Gessa GL, Serra G (2000) The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 405:365-373
8. 2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry 35:28-32
9. Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, Price JL, Mathis CA (2001) Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 49:81-96
10. Dunlop BW, Nemeroff CB (2007) The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64:327-337
11. Dupont WD, Plummer WD (1990) Power and sample size calculations: a review and computer program control. Control Clin Trials 11:116-128
12. 2 receptor SPECT before and after antidepressant therapy. Psychopharmacology 126:91-94
13. 11C]MNPA in cynomolgus monkey. Nucl Med Biol 32:353-360
14. First MB, Spitzer RL, Gibbon M, Williams JB (1997) Structured clinical interview for DSM-Axis I disorders-clinician version (SCID-CV). American Psychiatric, Washington, DC
15. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith C, Frackowiak RSJ (1995) Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 2:189-210
16. 2-like receptors and the antidepressant response. Biol Psychiatry 61:145-153
17. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 6:279-287
18. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296
19. 11C]raclopride. Nucl Med Commun 24:1207-1214
20. 2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry 62:371-378
21. Hirvonen J, van Erp TG, Huttunen J, Någren K, Huttunen M, Aalto S, Lönnqvist J, Kaprio J, Cannon TD, Hia J et al (2006) Striatal dopamine D1 and D2 receptor balance in twins at increased genetic risk for schizophrenia. Psychiatry Res Neuroimaging 146:13-20
22. Hwang DR, Narendran R, Laruelle M (2005) Positron-labeled dopamine agonists for probing the high affinity states of dopamine subtype 2 receptors. Bioconjug Chem 16:27-31
23. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539 May
24. Joel D, Weiner I (2000) The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 96:451-474
25. Kapur S, Mann JJ (1992) Role of the dopaminergic system in depression. Biol Psychiatry 32:1-17
26. Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA (2002) Dopaminergic abnormalities in amygdaloid nuclei in major depression: a post-mortem study. Biol Psychiatry 52:740-748
27. 123I]IBZM SPECT. Psychiatry Res 90:91-101
28. 11C]raclopride binding and cognitive function in patients with depression. J Affect Disord 95:35-42
29. Laasonen-Balk T, Kuikka J, Viinamäki H, Husso-Saastamoinen M, Lehtonen J, Tiihonen J (1999) Striatal dopamine transporter density in major depression. Psychopharmacology 144:282-285
30. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158
31. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 203:423-451
32. Malhi GS, Berk M (2007) Does dopamine dysfunction drive depression. Acta Psychiatr Scand 115(Suppl 433):116-124
33. 123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 44:1090-1098
34. Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR, Huang Y, Simpson N, Ngo K, Van Heertum R, Laruelle M (2001) Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21:1034-1057
35. Meyer JH, Gunn RN, Myers R, Grasby PM (1999) Assessment of spatial normalization of PET ligand images using ligand-specific templates. Neuroimage 9:545-553
36. 11C] raclopride positron emission tomography study. Am J Psychiatry 163:1594-1602
37. 11C]raclopride. J Affect Disord 101:113-122
38. Nestler EJ, Carlezon WA Jr. (2006) The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59:1151-1159
39. Nieoullon A (2002) Dopamine and the regulation of cognition and attention. Prog Neurobiol 67:53-83
40. Paillere-Martinot ML, Bragulat V, Artiges E, Dolle F, Hinnen F, Jouvent R, Martinot JL (2001) Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry 158:314-316
41. 2 receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry 50:313-322
42. 11C]raclopride. Int J Neuropsychopharmacol 7:431-439
43. 11C]raclopride. J Cereb Blood Flow Metab 13:310-314
44. Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122:509-522
45. Schultz W (1998) Predictive reward signal of dopamine neurons. J Neurophysiol 80:1-27
46. 2 binding in depression. Psychol Med 127:1247-1256
47. Talvik M, Nordström AL, Okubo Y, Olsson H, Borg J, Halldin C, Farde L (2006) Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res 148(2-3):165-73
48. 2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology 126:277-280
49. Tzschentke TM (2001) Pharmacology and behavioural pharmacology of the mesocortical dopamine system. Prog Neurobiol 63:241-320
50. 11C]-(+)-PHNO. Biol Psychiatry 59:389-394